[12] The presence of FGFR fusions (FGFR3-BAIAP2L1) not only enhanced tumor cell proliferation, but also led to significant sensitivity to small kinase inhibitors (PD173074) in pre-clinical cellular and xenograft bladder cancer models, in contrast with FGFR3 mutant cell lines, which were not sensitive to kinase inhibition. The gene discussed is FGFR3; the disease is neoplasm.